Inclusion Criteria:  The first prescription of Dymista® nasal spray according to the summary of product characteristics (SPC) and patient information leaflet and independently from the patient's enrollment in the study. Patients with moderate to severe seasonal or perennial allergic rhinitis For Hong Kong and Malaysia: Adult and children of age ≥ 12 years For Taiwan: Adult and children of age ≥ 6 years. For Thailand: Adults and children of age ≥ 12 years with seasonal and/or perennial allergic rhinitis OR children of age 6-11 years with only seasonal allergic rhinitis Acute allergic rhinitis symptoms at the day of inclusion (i.e. VAS-Score ≥50 mm) Signed informed consent/assent from the patient and, if applicable, the parent(s) or legal guardian(s) in compliance with local requirements. Ability to understand and follow the instructions for using Dymista® nasal spray according to the patient information leaflet. Willingness to complete and return the Patient Card.  Exclusion Criteria:  VAS score <50 mm on day of inclusion Known allergic reaction from and/or intolerance to Dymista® nasal spray or any of the ingredients. Pregnancy/planned pregnancy or breastfeeding during this NIS Patients or parent(s)/legal guardians (as applicable) not able to fulfill study requirements according to the Investigator's opinion.